Current and future priorities for the development of optimal HIV drugs
Open accessThe DOI matches its Crossref record.
Abstract
PURPOSE OF REVIEW: To summarize global efforts to accelerate access to simpler, safer and more affordable antiretroviral drugs and how this has shaped HIV treatment policy over the last decade, and outline future priorities. Several expert consultations aimed at aligning opportunities for optimization of antiretroviral drugs have been convened by WHO in partnership with academic institutions, international agencies, innovators and manufacturers. The increased access to lifelong treatment for people living with HIV also brings about new challenges in the long-term use of antiretrovirals (ARVs). RECENT FINDINGS: The article describes the evolution of global research agenda on ARV optimization ascribing the characteristics of a target product profile, the importance of sequencing of first-line and second-line regimens, the role of programmatic data when looking at policy transition for new ARVs, inclusion of more subpopulations living with HIV, as well as the challenges in identifying what improvements can be made in an era where drugs are already safe, tolerable and efficacious. SUMMARY: Within a framework of evolving treatment harmonization and simplification, future therapeutic options in development must take into consideration safety and efficacy across a range of patient populations as well the mode of administration in the context of lifelong therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Venter, W. D. F., Sokhela, S., Simmons, B., Moorhouse, M., Fairlie, L., Mashabane, N., Serenata, C., Akpomiemie, G., Masenya, M., Qavi, A., et al. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(20)30241-1 · Cited by 269
Facilitating the use of the target product profile in academic research: a systematic review
Ibnidris, A., Liaskos, N., Eldem, E., Gunn, A., Streffer, J., Gold, M., Rea, M., Teipel, S., Gardiol, A., & Boccardi, M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05476-1 · Cited by 20
Corona, A., Onnis, V., Del Vecchio, C., Esposito, F., Cheng, Y.-C., & Tramontano, E. (2020) · Molecules · doi:10.3390/molecules25061338 · Cited by 19
“The allosteric inhibition of the polymerase function of RT was achieved in the 1990s [27] with non-nucleoside inhibitors (NNRTI) that are still in the first-line therapy [28], although displaying a fairly low genetic barrier to selection of resistant variants, among which K103N, Y181C, and Y188L are the most common [2…”
Method
Metadata
- Authors
- Vitoria, M., Rangaraj, A., Ford, N., & Doherty, M.
- Venue
- Current Opinion in HIV and AIDS
- Published
- 2019-03
- Volume
- 14
- Issue
- 2
- Pages
- 143-149
- ISSN
- 1746-630X (ISSN-L)
- OpenAlex
- W2903944096
- Cited by
- 50
- References
- 0
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current and future priorities for the development of optimal HIV drugs. https://app.cochat.ai/papers/10.1097/coh.0000000000000527
- The paper
- Vitoria, M., Rangaraj, A., Ford, N., & Doherty, M. (2019). Current and future priorities for the development of optimal HIV drugs. Current Opinion in HIV and AIDS. https://doi.org/10.1097/coh.0000000000000527
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.